Few categories in modern practice have grown as quickly as GLP-1-based peptide therapy. What started as a niche area of metabolic research has become one of the most requested categories in clinics nationwide, driven largely by patient interest in semaglutide- and tirzepatide-based protocols. For clinics, that surge in demand has created a real supply-chain question: where can we source...